MAP3K7 Antikörper (AA 101-400) (FITC)

Produktnummer ABIN7160055

Der Kaninchen Polyklonal Anti-MAP3K7-Antikörper wurde für validiert. Er ist geeignet, MAP3K7 in Proben von Human zu detektieren.

Kurzübersicht für MAP3K7 Antikörper (AA 101-400) (FITC) (ABIN7160055)

Target: MAP3K7 (Mitogen-Activated Protein Kinase Kinase Kinase 7 (MAP3K7))

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser MAP3K7 Antikörper ist konjugiert mit FITC

Applikation: Bitte anfragen

Produktdetails anti-MAP3K7 Antikörper (FITC)

Bindungsspezifität: AA 101-400

Kreuzreaktivität: Human

Aufreinigung: >95%, Protein G purified

Immunogen: Recombinant Human Mitogen-activated protein kinase kinase kinase 7 protein (101-400AA)

Isotyp: IgG

Anwendungsinformationen

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: Preservative: 0.03 % Proclin 300
Constituents: 50 % Glycerol, 0.01M PBS, PH 7.4

Konservierungsmittel: ProClin

Vorsichtsmaßnahmen: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: -20 °C,-80 °C

Informationen zur Lagerung: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Details zu MAP3K7

Target: MAP3K7 (Mitogen-Activated Protein Kinase Kinase Kinase 7 (MAP3K7))

Andere Bezeichnung: MAP3K7

Hintergrund:

Background: Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. Plays an important role in the cascades of cellular responses evoked by changes in the environment. Mediates signal transduction of TRAF6, various cytokines including interleukin-1 (IL-1), transforming growth factor-beta (TGFB), TGFB-related factors like BMP2 and BMP4, toll-like receptors (TLR), tumor necrosis factor receptor CD40 and B-cell receptor (BCR). Ceramides are also able to activate MAP3K7/TAK1. Once activated, acts as an upstream activator of the MKK/JNK signal transduction cascade and the p38 MAPK signal transduction cascade through the phosphorylation and activation of several MAP kinase kinases like MAP2K1/MEK1, MAP2K3/MKK3, MAP2K6/MKK6 and MAP2K7/MKK7. These MAP2Ks in turn activate p38 MAPKs, c-jun N-terminal kinases (JNKs) and I-kappa-B kinase complex (IKK). Both p38 MAPK and JNK pathways control the transcription factors activator protein-1 (AP-1), while nuclear factor-kappa B is activated by IKK. MAP3K7 activates also IKBKB and MAPK8/JNK1 in response to TRAF6 signaling and mediates BMP2-induced apoptosis. In osmotic stress signaling, plays a major role in the activation of MAPK8/JNK1, but not that of NF-kappa-B. Promotes TRIM5 capsid-specific restriction activity.

Aliases: M3K7_HUMAN antibody, MAP3K 7 antibody, Map3k7 antibody, MEKK7 antibody, Mitogen activated protein kinase kinase kinase 7 antibody, Mitogen-activated protein kinase kinase kinase 7 antibody, TAK1 antibody, TGF beta activated kinase 1 antibody, TGF-beta-activated kinase 1 antibody, TGF1a antibody, Transforming growth factor beta activated kinase 1 antibody, Transforming growth factor-beta-activated kinase 1 antibody

UniProt: O43318

Pathways: NF-kappaB Signalweg, T-Zell Rezeptor Signalweg, TLR Signalweg, Fc-epsilon Rezeptor Signalübertragung, Activation of Innate immune Response, Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Production of Molecular Mediator of Immune Response, Tube Formation, Toll-Like Receptors Cascades, BCR Signaling, Ubiquitin Proteasome Pathway